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A 39-year-old right-handed agricultural service engineer developed rapidly evolving severe
relapsing-remitting multiple sclerosis (MS). MRI showed multiple T2 hyperintensities
throughout his neuroaxis (figure, A). Several lesions showed restricted diffusion, and 2 en-
hanced. He received steroids for each relapse, making a full recovery (Expanded Disability
Status Score [EDSS] 0).
There was clinical equipoise between induction therapy with alemtuzumab or natalizumab. He
was JC virus positive. He chose treatment with alemtuzumab, partly because of the even chance
that after 2 cycles, he might not require further treatment, plus the ease of administration, vs the
longer-term risks with natalizumab.
Nine months after the first cycle of alemtuzumab, he represented with an encephalopathic
picture and progressive focal neurology. He had a headache for 12 days, diplopia for 8 days, and
became confused and unsteady on his feet over 5 days. He was apyrexial, looked unwell, was
drowsy, and disorientated. Diplopia was present in all directions, and he had mild left upper
motor neurone facial weakness and proximal weakness of his lower limbs. Reflexes were difficult
to elicit, with upgoing plantars. He deteriorated markedly over the subsequent week, de-
veloping ophthalmoplegia, tetraparesis, inability to communicate, and respiratory compromise
requiring intubation (EDSS 9.5).
Serum and CSF markers of infection were all negative, including listeria, but his CSF was active
with significantly elevated lymphocytes (200 cells/mm3; 90% lymphocytes) and protein (0.85
g/L); glucose was normal. CSF showed unmatched oligoclonal bands. Aquaporin-4 and MOG
antibodies were negative.
CSF cytology confirmed reactive lymphocytes (85%). Flow cytometry reported 59% T cells
(CD4:CD8 2:1), 35% B cells (kappa:lambda 1.4:1), and 3% NK cells. An additional 13% had
a larger morphology and phenotype profile consistent with plasma cells, strongly expressing
CD45 and CD38, moderately expressing CD81+, and weakly expressing CD19 and light chains.
Repeat brain MRI revealed numerous new white matter lesions. Most showed restricted
diffusion, suggestive of acute demyelination (figure, B), but there was no enhancement
(postgadolinium images not shown). EEG showed nonspecific generalized slowing, consistent
with generalized cerebral dysfunction/encephalopathy.
His presentation was consistent with encephalitis, with an infective or inflammatory cause.
Acyclovir, ceftriaxone, and amoxicillin were administered early, followed by 3,000 mg IV
methylprednisolone over 3 days and 10 cycles of alternate day plasma exchange.
There was no clinical response, and repeat MRI brain showed progression (figure, C), still
without contrast enhancement (not shown). Severe B cell–mediated demyelination was
From Jesus College (J.B., S.R.L.S.), Cambridge University, UK; Department of Neurology (J.L.J., S.R.L.S.), Addenbrooke’s Hospital, CambridgeUniversity Hospitals NHS Foundation Trust,
Cambridge, UK; and Department of Neurology (S.R.L.S.), Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, UK.
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by the Wellcome Trust.
This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 1
suspected. Rituximab was commenced and continued 6
monthly, alongside 3 cycles of cyclophosphamide. Sub-
sequent gradual improvement resulted in a remarkable func-
tional recovery (EDSS 3.5 two years later with return to full
time work) along with significant remyelination and resolu-
tion of T1 black holes (figures, D and E).
Discussion
The first 2 cases of paradoxical disease activation in patients
with MS treated with alemtuzumab were reported in 2017.1
The authors proposed that a secondary B cell–driven auto-
immune disease targeting the CNS and appearing similar to
MS could occur after alemtuzumab therapy due to the ob-
servation that B-cell numbers recover far more quickly after
alemtuzumab than CD4+ and CD8+ T cells, sometimes
overshooting pretreatment levels.1 However, the relative ki-
netics of B- and T-cell recovery have no effect on the risk of
non–CNS-directed autoimmunity. Rather, the risk of de-
veloping Graves disease and immune thrombocytopenia after
alemtuzumab is associated with poor thymic T-cell recovery
and exaggerated CD4+ T-cell homeostatic proliferation.2 CNS-
directed alemtuzumab-induced autoimmunity is also unlikely
to be due to numerical differences in B- and T-cell counts.
Instead, this acute disseminated encephalomyelitis-like illness
after alemtuzumab is more likely to result from the complex
interplay of multiple reconstituting immune cell subsets.
Eleven of the other 17 reported cases of disease activation
after alemtuzumab occurred in those switching therapies di-
rectly from fingolimod,1,3,4 suggesting confounding of path-
ologic mechanisms. Following treatment with fingolimod,
many lymphocytes remain hidden from the intravascular
therapeutic effects of alemtuzumab due to selective lymphoid
sequestration. Later egression could initiate rebound activity,
which also occurs if fingolimod treatment is stopped without
substituting a different therapy.3 This disease activity would
be due to a failure of alemtuzumab to bind to CD52+-
lymphocytes, not the repopulation kinetics of B and T cells
after treatment.
Figure Evolving imaging features at diagnosis, representation, 3 and 5 weeks later, and after 17 months
(A) MRI of the brain and spinal cord at the point of diagnosis with
rapidly evolving relapsing-remittingMS. His initial demyelinating event
involved the brainstem andmedial longitudinal fasciculus with several
areas of involvement in the cerebral cortex. The second event localized
to the lower spinal cord, with no evidence of involvement of the cervical
spine. (B) MRI of the brain the day after representation, 9 months after
the first cycle of alemtuzumab. T2-weighted imaging showed multiple
new areas throughout the brain. Diffusion-weighted imaging con-
firmed appearances suggestive of acute demyelination with multiple
areas of restricted diffusion. (C) MRI of the brain and cervical spine 3
weeks after representation. T2-weighted images show extensive de-
myelination in the brainstem, cerebral cortex, and cervical spine. (D)
MRI of the brain at nadir, 5 weeks after representation. T2-weighted
imaging illustrates extensive demyelination with areas of T1 signal
change. (E) MRI of the brain 17 months later showing remarkable
resolution over time.
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One question on encountering paradoxical disease activation
after alemtuzumab is whether to proceed to the second
treatment cycle or switch to rituximab (or an alternative anti-
CD20 B-cell therapy such as ocrelizumab). Five patients in
the literature received rituximab; 6 including ours. All have
responded well. Willis’ case series of disease activity 4–5
months post-alemtuzumab in patients switched from fin-
golimod responded well to the second cycle of alemtuzu-
mab, as might be expected from the mechanisms discussed
above.
We hope that the remarkable recovery of our patient, despite
extensive brainstem involvement, will provide clinicians with
the confidence to treat in such severe situations.
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